KR102607247B1 - Composition for Anticancer Comprising Cyrtomium falcatum extract - Google Patents

Abstract

The present invention relates to food compositions, pharmaceutical compositions, food additive compositions, health functional foods, and feed compositions for the prevention or improvement of cancer containing extracts of the Goblin fern as an active ingredient.
The Dokkaebi Gobi extract according to the present invention has an anticancer effect, and food compositions, pharmaceutical compositions, food additive compositions, health functional foods, and feed compositions containing the Dokkaebi Gobi extract as an active ingredient are used for the prevention, treatment, or improvement of cancer. It can be useful.

Description

Anticancer composition containing the extract of the goblin falcatum as an active ingredient {Composition for Anticancer Comprising Cyrtomium falcatum extract}

The present invention relates to food compositions, pharmaceutical compositions, food additive compositions, health functional foods, and feed compositions for the prevention or improvement of cancer containing extracts of the Goblin fern as an active ingredient.

Despite the development of modern medicine, cancer is still one of the human diseases that is difficult to treat. Cancer is a tissue made up of abnormal cells that originate in one or more tissues and spread to other tissues. There are currently more than 100 known types of cancer.

It is known that 90-95% of the main causes of cancer are genetic mutations caused by environmental factors, and most of these factors include smoking, obesity, radiation, UV, stress, and environmental pollution.

Among them, colorectal cancer is a malignant tumor made up of cancer cells in the large intestine. According to data from the Central Cancer Registry Headquarters published in 2019, it ranked second with 28,111 cases in both men and women, or 12.1% of the total, with a trillion incidence rate per 100,000 people. (The number of newly occurring patients in the target population group during the relevant observation period. The crude mortality rate is also calculated based on the same criteria) is 54.9 cases, which is an extremely high incidence rate.

Risk factors for developing colon cancer include dietary factors, obesity, genetic factors, adenomatous polyps, inflammatory bowel disease, lack of physical activity, drinking, and age over 50, and the incidence tends to increase with age.

Liver cancer is a malignant tumor originating from liver cells. The most common causes of liver cancer are chronic hepatitis B or C, persistent excessive drinking, and liver cirrhosis. If destruction and regeneration of the liver is repeated due to viral infection or alcohol, the risk of liver cancer increases significantly.

Current treatment methods for cancer include chemotherapy using drugs such as antimetabolites, alkylating agents, topoisomerase inhibitors, and monoclonal antibodies, or radiation therapy simultaneously. It is also used. However, the use of these drugs may vary depending on the individual patient, but in general, there are side effects such as hair loss, bone marrow function suppression, drug resistance, and organ damage. Numerous efforts are being made around the world to overcome these side effects and conquer cancer, and as part of these efforts, research to prevent the growth of cancer using natural products is active.

Meanwhile, Dokkaebi Gobi is a medicinal plant that grows on the beaches of Korea's Jeju Island, Ulleungdo Island, and the southern part of the central region. In oriental medicine, it is called ‘Jeon Yeon Gwan-jung’, and is effective in killing insects and hemostasis, so it has been mainly used to treat hookworm disease and uterine bleeding. Research on the goby goby is a plant resource with only reports on growth conditions, etc., and research on its physiological activity is still insufficient.

Under this background, the present inventors made extensive research efforts to develop natural materials useful for the prevention or treatment of cancer. As a result, they confirmed the cancer cell killing effect of the Dokkaebi Gobi extract and confirmed its applicability as an anticancer material, thereby completing the present invention.

Republic of Korea Patent Publication No. 10-2013-0113626

The present invention aims to solve the above-described problems and other problems associated therewith.

An exemplary object of the present invention is to provide a food composition for preventing or improving cancer containing Cyrtomium falcatum extract as an active ingredient.

Another exemplary object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of cancer containing an extract of Dokkaebi Gobi as an active ingredient.

Another exemplary object of the present invention is to provide a food additive composition for preventing or ameliorating cancer, containing an extract of Goblin goby as an active ingredient.

Another exemplary object of the present invention is to provide a health functional food for preventing or improving cancer containing an extract of Gobi gobi as an active ingredient.

Another exemplary object of the present invention is to provide a feed composition for preventing or ameliorating cancer containing an extract of Goblin goby as an active ingredient.

The technical problem to be achieved according to the technical idea of the invention disclosed in this specification is not limited to the problem to solve the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description below. There will be.

This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in the present application may also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in this application fall within the scope of this application. Additionally, the scope of the present application cannot be considered limited by the specific description described below.

As an aspect for achieving the above object, the present invention provides a food composition for preventing or improving cancer containing an extract of the Goblin goby as an active ingredient.

The term "doggaebi fern" in the present invention is an evergreen perennial herb belonging to the genus of the Myeongeaceae family, and is an evergreen fern that grows naturally on coastlines and islands across the country, including Jeju Island and Ulleungdo Island. It is reported that goblin gobi mainly has antipyretic, hemostatic, and insecticidal effects.

The term "extract" in the present invention refers to an extract, such as an extract obtained by extraction treatment of the above-mentioned Goblin Gobi, a diluted or concentrated liquid of the above-mentioned extract, a dried product obtained by drying the extract, a crude product or purified product of the above-described extract, or a mixture thereof. Includes extracts of all formulations that can be formed on their own and using extracts.

In the present invention, the extraction is not particularly limited and can be extracted according to methods commonly used in the art. Non-limiting examples of the extraction method include hot water extraction, cold immersion extraction, solvent extraction, steam distillation, elution, compression, ultrasonic extraction, filtration, and reflux extraction, which are performed alone or using a combination of two or more methods. It can be performed by doing this.

The extract of the present invention is obtained by extracting Gobi Gobi using an appropriate solvent, and may include, for example, a crude extract, a polar solvent-soluble extract, or a non-polar solvent-soluble extract. The type of extraction solvent used to prepare the extract is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water; Alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol, butanol, propyl alcohol, and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol, and propylene glycol; Hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; Alternatively, a mixture thereof may be used. For example, it may be a solvent selected from the group consisting of water, alcohol with 1 to 4 carbon atoms, or a mixed solvent thereof.

In the present invention, the Dokkaebi fern extract may be a whole plant, leaf, stem, or root extract of the Dokkaebi fern, and for example, it may be a Dokkaebi fern root extract.

The term "prevention" of the present invention refers to any action that inhibits or delays cancer through administration of the composition of the present invention, and the term "treatment" of the present invention refers to improvement or alleviation of cancer caused by administering the composition of the present invention. It means any action that becomes or changes beneficially. The term “improvement” in the present invention refers to all actions in which cancer is improved by administration of the composition.

In the present invention, cancer includes oral cancer, prostate cancer, rectal cancer, non-small cell lung cancer, lip cancer, stomach cancer, colon cancer, liver cancer, lung cancer, anal cancer, kidney cancer, vulvar cancer, oropharyngeal cancer, nasal cavity/paranasal sinus cancer, nasopharyngeal cancer, It may be urethral cancer, small intestine cancer, biliary tract cancer, bladder cancer, ovarian cancer, laryngeal cancer, or esophageal cancer, but is not limited thereto.

Specifically, in an experimental example of the present invention, it was confirmed that the Dokkaebi Gobi extract had an anticancer effect on colon cancer cells and liver cancer cells, and compared to the Sanghwang mushroom extract, which is known to have anticancer effects, the Dokkaebi Gobi extract had a higher effect on liver cancer cells and colon cancer cells. It was confirmed that it exhibits anti-cancer effects. In addition, it was confirmed that the protein expression levels of Bax, p53, and p21, proteins related to apoptosis, increased when liver cancer cells were treated with gradually increasing concentrations of Gobi goby extract.

Based on these test examples, it was confirmed that the Goblin Gobi extract of the present invention can be usefully used for the prevention, improvement, or treatment of cancer.

The food composition of the present invention can be manufactured in various types of formulations, and unlike general drugs, it has the advantage of being made from food as a raw material and having no side effects that may occur when taking the drug for a long period of time. The food composition of the present invention can be manufactured in any form, and specifically, health functional food preparations such as tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jellies, bars, etc. It may be one or more formulations selected from the group consisting of beverages, gums, and candies, but is not particularly limited thereto.

Additionally, the food composition of the present invention may contain food additives in addition to the active ingredients. Food additives can generally be understood as substances that are added to, mixed with, or infiltrated into food when manufacturing, processing, or preserving food. Since they are consumed daily and for a long period of time with food, their safety must be guaranteed. The food additives are classified into sweeteners, flavorants, preservatives, emulsifiers, acidulants, thickeners, etc. in terms of function, and are not particularly limited as long as they meet the purpose to be achieved by the food composition of the present invention. In addition, the food composition of the present invention may contain, in addition to the food additives, bioactive substances or minerals known in the art for the purpose of functionality and nutritional supplementation and whose safety is guaranteed as food additives. The physiologically active substances or minerals are not particularly limited as long as they meet the purpose to be achieved by the food composition of the present invention.

The food composition of the present invention may contain the above-mentioned food additives in an effective amount to achieve the purpose of addition depending on the product type, and with respect to other food additives that may be included in the food composition of the present invention, each country's food code You can also refer to the Food Additives Code.

In another aspect of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of cancer containing an extract of Goblin goby as an active ingredient.

The terms “goblin gobi,” “extract,” “prevention,” “treatment,” and “cancer” in the present invention are as described above.

The term “pharmaceutical composition” of the present invention refers to a product prepared for the purpose of preventing or treating disease, and can be formulated and used in various forms according to conventional methods.

The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent according to a conventional method. Pharmaceutically acceptable carriers are well known in the art depending on the administration route or dosage form, and for specifics, each country's pharmacopoeia, including the 'Korean Pharmacopoeia', can be referred to. Carriers, excipients and diluents that may be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, Examples include, but are not limited to, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. Additionally, carriers, excipients, and diluents that may be included in the composition of the present invention may be unnatural carriers, but are not limited thereto.

The pharmaceutical composition of the present invention can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external preparations, suppositories, or sterile injectable solutions according to conventional methods. . In detail, it can be prepared using commonly used diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are made by adding at least one excipient to the compound, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. It can be prepared by mixing. Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc can also be used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups. In addition to the commonly used simple diluents such as water and liquid paraffin, they contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives. You can. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As a base for suppositories, wethepsol, macrogol, Tween 61, cacao, laurin, glycerogelatin, etc. can be used. Regarding the specific formulation of pharmaceutical compositions, it is known in the art, and references can be made to, for example, Remington's Pharmaceutical Sciences (19th ed., 1995). The above documents are considered a part of this specification.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The pharmaceutically effective amount refers to an amount that is sufficient to treat the disease at a reasonable benefit/risk ratio applicable to medical treatment and does not cause side effects. The effective dose level refers to the patient's health status, type and severity of the disease, It can be determined based on factors including the activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration and excretion rate, duration of treatment, drugs combined or used simultaneously, and other factors well known in the medical field. The dosage and frequency of administration do not limit the scope of the present invention in any way.

The pharmaceutical composition of the present invention can be administered through various routes to mammals such as rats, dogs, cats, cows, horses, pigs, and humans, and humans may be preferable. All modes of administration are contemplated and may include, but are not limited to, oral, intravenous, intramuscular or subcutaneous injection.

The pharmaceutical composition of the present invention may have a preventive or therapeutic effect on cancer.

The term "including as an active ingredient" in the present invention means that the pharmaceutical composition contains an effective amount capable of exhibiting an anti-cancer effect.

In another aspect of the present invention, the present invention provides a food additive composition for preventing or ameliorating cancer, comprising an extract of Dokkaebi Gobi as an active ingredient.

The terms “goblin gobi,” “extract,” “prevention,” and “improvement” in the present invention are as described above.

In the present invention, the term "food additive" is used by adding, mixing, infiltrating and other methods to food for the purpose of improving preservation, improving quality, enhancing nutrition, improving flavor and appearance when manufacturing, processing or preserving food. It can mean a substance that becomes The food additive can be added as is with the active ingredient of the present invention or used together with other food or food ingredients, and the mixing amount of the active ingredient can be appropriately determined by a person skilled in the art depending on the purpose of use. The food additive composition containing the extract of Gobi gobi of the present invention can achieve the effect of preventing or improving liver cancer or colon cancer in addition to the food or food ingredient to which it is added.

In another aspect of the present invention, the present invention provides a health functional food for preventing or improving cancer containing an extract of Gobi Gobi as an active ingredient.

The terms “goblin gobi,” “extract,” “prevention,” and “improvement” in the present invention are as described above.

In the present invention, the term “health functional food” refers to food manufactured and processed using raw materials or ingredients with functional properties useful to the human body. The term “functionality” refers to obtaining effects useful for health purposes, such as controlling nutrients or physiological effects on the structure and function of the human body. The health functional food of the present invention can be manufactured by a method commonly used in the art, and can be manufactured by adding raw materials and components commonly added in the art during production.

In addition, the formulation of the health functional food can be manufactured without limitation as long as it is a formulation recognized as a health functional food. Non-limiting examples of the formulation include tablets, capsules, pills, granules, liquid, powder, flakes, paste, syrup, It may be one or more formulations selected from the group consisting of health functional food preparations such as gels, jellies, bars, beverages, gums, and candies, but is not particularly limited thereto.

In yet another aspect of the present invention, the present invention provides a feed composition for preventing or improving cancer containing an extract of Gobi Gobi as an active ingredient.

The feed composition may include feed additives. The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act.

In the present invention, the term "feed" may mean any natural or artificial diet, meal, etc., or a component of the meal, especially for or suitable for eating, ingestion, and digestion by animals.

The type of feed is not particularly limited, and feed commonly used in the art can be used. Non-limiting examples of the feed include plant feeds such as grains, roots and fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, cucurbits or grain by-products; Examples include animal feeds such as proteins, inorganic substances, fats and oils, minerals, oils and fats, single-cell proteins, zooplanktons or foods. These may be used individually or in combination of two or more types.

The Dokkaebi Gobi extract according to the present invention has an anticancer effect, and food compositions, pharmaceutical compositions, food additive compositions, health functional foods, and feed compositions containing the Dokkaebi Gobi extract as an active ingredient are used for the prevention, treatment, or improvement of cancer. It can be useful.

Figure 1 shows the results of confirming the anticancer effect of Dokkaebi Gobi root extract on colon cancer and liver cancer.
Figure 2 shows the results of comparing the anticancer effects of Dokkaebi Gobi root extract and Sanghwang mushroom extract on colon cancer.
Figure 3 shows the results of comparing the anticancer effects of Dokkaebi Gobi root extract and Sanghwang mushroom extract on liver cancer.
Figure 4 shows the results of comparing the cell survival rates of hepatocytes and liver cancer cells after treatment with Gobi fern root extract.
Figure 5 shows the results of confirming the expression level of apoptosis-related proteins (p53, p21, Bax) in liver cancer cells after treatment with the Gobi fern root extract.

Hereinafter, the configuration and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.

Example 1: Preparation of compositions according to the invention

After separating the roots and leaves of Dokkaebi Gobi grown in Yongin-si, Gyeonggi-do, they were dried at 50°C for 1 day, the samples were ground, and distilled water was added and extracted three times, once at room temperature. The obtained extract was filtered through filter paper and concentrated under reduced pressure to prepare Dokkaebi fern root extract.

Experimental Example 1: Confirmation of anti-cancer effect of Dokkaebi Gobi extract

1-1. cell culture

To confirm the anticancer effect of the Dokkaebi Gobi extract on cancer cells, human liver cancer cell line (HepG2), human colon cancer cell line (HT-29), and normal liver cell line (AML-12) were cultured.

Specifically, HepG2 cells and HT-29 cells were grown in DMEM (Gibco) medium containing 10% FBS (Gibco. Rockville, MD, USA), 100 U/mL penicillin and 100 μg/mL streptomycin (Gibco) at 37°C. Cultured under 5% CO ₂ .

AML-12 cells, a normal liver cell line, were cultured in DMEM containing 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 0.1 μM dexamethasone (Sigma-Aldrich, St Louis, MO, USA), and 1% ITS (Gibco). /F12 (Gibco) medium was cultured at 37°C and 5% CO ₂ .

1-2. Check survival rate by cell

In order to confirm whether the Dokkaebi fern extract has an anticancer effect on cancer cells, the cell viability was measured by adding the Dokkaebi fern root extract to liver cancer and colon cancer cells.

Specifically, HepG2 cells were distributed and cultured in a 96 well plate at 1x10 ⁴ cells/well, and HT-29 and AML-12 cells were distributed at 2x10 ⁴ cells/well. The next day, the root extract of Dokkaebi fern was treated at different concentrations to 0, 50, 100, and 200 ppm and cultured for 24 hours. Afterwards, 0.1 mg/mL MTT solution was added and cultured for 2 hours. The medium was removed, DMSO was added to dissolve the formazan crystals formed within the cells, and the absorbance was measured at 540 nm using a microplate reader. Results were expressed as a percentage of the group that did not treat the sample.

As a result, as shown in Figure 1, the cancer cell survival rate of colon cancer cells (HT-29) and liver cancer cells (HepG2) treated with the Dokkaebi fern root extract showed a tendency for the cancer cell survival rate to decrease significantly as the treatment concentration increased. It was confirmed that the extract exhibited excellent activity against colon cancer and liver cancer.

1-3. Cancer cell survival rate confirmed compared to Sanghwang mushroom extract

Sanghwang mushroom is classified as a genus of mud mushrooms of the pellinus linteus family. Its anticancer effect has been previously confirmed, and it is known to have higher anticancer activity than other basidiomycetes. Polysaccharides or protein polysaccharides within the mycelium, known as the anti-tumor active ingredients of Sanghwang mushrooms, are known to have an anti-cancer effect by conferring an immune-boosting effect on cells in the human body.

In order to compare the anti-cancer effect of the Dokkaebi fern extract of the present invention with that of the Sanghwa mushroom extract, which is known to have anti-cancer efficacy, colon cancer cells (HT-29) and liver cancer cells (HepG2) were treated with the Sanghwa fern root extract and Sanghwa mushroom extract, respectively, and the cell viability was measured. was compared.

Specifically, Sanghwang mushrooms grown in Sancheong-gun, Gyeongsangnam-do were extracted using water in the same manner as Dokkaebi Gobi to prepare Sanghwang mushroom extracts, and then the Sanghwang mushroom extract and Sanghwang mushrooms were added to HT-29 cells and HepG2 cells cultured in the same manner as in 1-2. Mushroom extracts were treated at different concentrations to 50, 100, and 200 ppm, respectively, and cultured for 24 hours. Afterwards, 0.1 mg/mL MTT solution was added and cultured for 2 hours. The medium was removed, DMSO was added to dissolve the formazan crystals formed within the cells, and the absorbance was measured at 540 nm using a microplate reader. Results were expressed as a percentage of the group that did not treat the sample.

As a result, as shown in Figures 2 and 3, when colon cancer cells (HT-29) and liver cancer cells (HepG2) were treated with Dokkaebi fern root extract and Sanghwang mushroom extract, respectively, as the treatment concentration increased, Dokkaebi fern compared to Sanghwang mushroom The cell survival rate in the fern extract showed a tendency to significantly decrease, confirming that the Dokkaebi fern extract had a significantly superior anticancer effect compared to the Sanghwang mushroom extract.

1-4. Toxicity check

In order to confirm the toxicity of the Dokkaebi fern extract to hepatocytes, normal hepatocytes (AML12) and hepatoma cells (HepG2) were treated with the Dokkaebi fern root extract.

Specifically, AML12 and HepG2 cells cultured in 1-1 were treated with different concentrations of 50, 100, and 200 ppm of Gobi fern root extract, respectively, and cultured for 24 hours. 0.1 mg/mL MTT solution was added and cultured for 2 hours. The medium was removed, DMSO was added to dissolve the formazan crystals formed within the cells, and the absorbance was measured at 540 nm using a microplate reader. Results were expressed as a percentage of the group that did not treat the sample.

As a result, as shown in Figure 4, there was no significant change in cell viability of hepatocytes treated with Dokkaebi fern root extract regardless of the treatment concentration, but when liver cancer cells were treated with Dokkaebi fern root extract, the cell viability was higher than that of hepatocytes. It was low, and as the treatment concentration increased, the cell survival rate tended to decrease significantly.

Through this, it was confirmed that the Dokkaebi fern root extract had low toxicity to liver cells and high toxicity to liver cancer cells.

1-5. Confirmation of increased expression of apoptotic proteins

To confirm the anticancer effect of the Dokkaebi fern extract, liver cancer cells were treated with the Dokkaebi fern root extract and the expression levels of Bax, p53, and p21 proteins related to apoptosis were checked.

Specifically, 5x10 ⁶ liver cancer cells were cultured in a 60 mm dish, treated with 0, 50, and 100 ppm of Dokkaebi fern root extract, respectively, and cultured for 24 hours. Then, the cells were collected by centrifugation at 1,000 rpm for 5 minutes, and then washed with cold phosphate. Washed twice with buffer saline (PBS; Gibco). Afterwards, proteins were extracted by treatment with RIPA buffer (Sigma-Aldrich) containing protease/phosphatase inhibitor cocktail (Cell signaling Technology, Beverly, MA, USA) at 4°C for 30 minutes. The extracted protein was quantitatively analyzed using the BCA protein assay kit (Thermofisher scientific, Waltham, MA, USA), and then an equal amount of protein was loaded onto a gradient gel and electrophoresed at 100 voltage for 80 minutes. Proteins separated on the gel were transferred to a PVDF membrane and blocked with 5% non-fat dried milk in TBST for 1 hour at room temperature. Primary antibodies anti-p21 (Abcam, Cambridge, MA, UK), anti-p53, Bax (Cell signaling Technology) and actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were diluted 1:1000 with blocking solution. Reaction was performed at 4°C for 16 hours. After washing with TBST three times for 5 minutes, the secondary antibody anti-rabbit or anti-mouse antibody was diluted with TBST and reacted at room temperature for 1 hour. After washing with TBST four times for 10 minutes, the ECL kit was used. Protein expression was confirmed using .

As a result, as shown in Figure 5, it was confirmed that the expression levels of Bax, p53, and p21, which are related to cancer cell death, increased as the concentration of the root extract of Dokkaebi fern treated with liver cancer cells increased.

Through this, the anticancer effect of Dokkaebi Gobi root extract on liver cancer cells was confirmed.

From the above description, those skilled in the art to which the present invention pertains will understand that the present invention can be implemented in other specific forms without changing its technical idea or essential features. In this regard, the embodiments described above should be understood in all respects as illustrative and not restrictive. The scope of the present invention should be construed as including the meaning and scope of the patent claims described below rather than the detailed description above, and all changes or modified forms derived from the equivalent concept thereof are included in the scope of the present invention.

Claims (13)

A food composition for preventing or improving liver cancer containing Cyrtomium falcatum extract as an active ingredient.
According to paragraph 1,
A food composition, characterized in that the extract is extracted with a solvent selected from the group consisting of water, alcohols having 1 to 4 carbon atoms, or mixed solvents thereof.
According to paragraph 1,
The extract is a food composition extracted from the leaves, stems, roots, or mixtures thereof.
delete A pharmaceutical composition for preventing or treating liver cancer comprising Cyrtomium falcatum extract as an active ingredient.
According to clause 5,
A pharmaceutical composition, characterized in that the extract is extracted with a solvent selected from the group consisting of water, alcohols having 1 to 4 carbon atoms, or mixed solvents thereof.
According to clause 5,
The extract is a pharmaceutical composition extracted from the leaves, stems, roots, or mixtures thereof.
delete A food additive composition for preventing or improving liver cancer, comprising an extract of the Goblin fern as an active ingredient.
A health functional food for the prevention or improvement of liver cancer containing the extract of Dokkaebi Gobi as an active ingredient.
According to clause 10,
The health functional food is one or more selected from the group consisting of health functional food preparations such as tablets, capsules, pills, granules, liquids, powders, flakes, pastes, syrups, gels, jellies, bars, beverages, gums, and candies. It is a health functional food in dosage form.
A feed composition for preventing or ameliorating liver cancer containing an extract of Dokkaebi Gobi as an active ingredient. delete